




Searching News Database: biosimilar
HSMN NewsFeed - 31 Jan 2025
U.S. FDA Approves Celltrion's AVTOZMA(R) (tocilizumab-anoh), a Biosimilar to ACTEMRA(R)
U.S. FDA Approves Celltrion's AVTOZMA(R) (tocilizumab-anoh), a Biosimilar to ACTEMRA(R)
HSMN NewsFeed - 15 Jul 2024
HanAll Biopharma Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer
HanAll Biopharma Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer
HSMN NewsFeed - 30 Apr 2024
Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer (CBO)
Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer (CBO)
HSMN NewsFeed - 2 Feb 2023
Tezspire(R) Approved for Self-Administration in the U.S. with a New Pre-Filled Pen
Tezspire(R) Approved for Self-Administration in the U.S. with a New Pre-Filled Pen
HSMN NewsFeed - 26 Jan 2023
Cardinal Health Teams Up with Palantir to Deliver a Clinically Integrated Supply Chain Solution
Cardinal Health Teams Up with Palantir to Deliver a Clinically Integrated Supply Chain Solution
HSMN NewsFeed - 25 Oct 2022
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
HSMN NewsFeed - 3 Jan 2022
Biosion, Inc. Appoints Anthony Yeh, Ph.D., as Chief Strategy Officer and Head of China BD
Biosion, Inc. Appoints Anthony Yeh, Ph.D., as Chief Strategy Officer and Head of China BD
HSMN NewsFeed - 15 Apr 2021
Valeo Pharma Announces Commercial Launch of Redesca(TM) and Redesca HP(TM)
Valeo Pharma Announces Commercial Launch of Redesca(TM) and Redesca HP(TM)
HSMN NewsFeed - 9 Feb 2021
Lannett Expands Strategic Relationship To Include Biosimilar Fast-Acting Insulin
Lannett Expands Strategic Relationship To Include Biosimilar Fast-Acting Insulin
HSMN NewsFeed - 13 Jan 2021
EVOQ Therapeutics Announces a License And Collaboration Agreement with Amgen
EVOQ Therapeutics Announces a License And Collaboration Agreement with Amgen
HSMN NewsFeed - 22 Dec 2020
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
HSMN NewsFeed - 9 Dec 2020
Valeo Pharma Announces Health Canada Approval for Redesca(TM) and Redesca Hp(TM)
Valeo Pharma Announces Health Canada Approval for Redesca(TM) and Redesca Hp(TM)
HSMN NewsFeed - 3 Sep 2020
Innovent Announces NMPA Granted Marketing Approval for SULINNO(R) (Adalimumab Injection) in China
Innovent Announces NMPA Granted Marketing Approval for SULINNO(R) (Adalimumab Injection) in China
HSMN NewsFeed - 24 Jul 2020
Bimekizumab Superior to Cosentyx(R) in Achieving Complete Psoriasis Skin Clearance
Bimekizumab Superior to Cosentyx(R) in Achieving Complete Psoriasis Skin Clearance
HSMN NewsFeed - 11 Jun 2020
Lannett Provides Update On Clinical Advancement Of Biosimilar Insulin Glargine, Following FDA Meeting
Lannett Provides Update On Clinical Advancement Of Biosimilar Insulin Glargine, Following FDA Meeting
HSMN NewsFeed - 4 Jun 2020
Mylan and Lupin Receive European Marketing Authorization for Nepexto(R), Biosimilar Etanercept
Mylan and Lupin Receive European Marketing Authorization for Nepexto(R), Biosimilar Etanercept
HSMN NewsFeed - 2 Jan 2020
Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China
Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China
HSMN NewsFeed - 30 Oct 2019
Biogen and Alkermes Announce FDA Approval of VUMERITY(TM) (diroximel fumarate) for Multiple Sclerosis
Biogen and Alkermes Announce FDA Approval of VUMERITY(TM) (diroximel fumarate) for Multiple Sclerosis
HSMN NewsFeed - 24 Oct 2019
Amgen To Make Repatha(R) (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
Amgen To Make Repatha(R) (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
HSMN NewsFeed - 18 Oct 2019
Nplate(R) (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
Nplate(R) (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
HSMN NewsFeed - 28 Jun 2019
Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU
Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU
HSMN NewsFeed - 14 May 2019
Boehringer Ingelheim announces resolution of Cyltezo(R) patent litigation
Boehringer Ingelheim announces resolution of Cyltezo(R) patent litigation
HSMN NewsFeed - 14 May 2019
AbbVie Resolves HUMIRA(R) (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim
AbbVie Resolves HUMIRA(R) (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim
HSMN NewsFeed - 15 Apr 2019
Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion
Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion
HSMN NewsFeed - 13 Mar 2019
Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA(R)
Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA(R)
HSMN NewsFeed - 11 Feb 2019
Foresee Pharmaceuticals Enters Exclusive License Agreement with Accord Healthcare
Foresee Pharmaceuticals Enters Exclusive License Agreement with Accord Healthcare
HSMN NewsFeed - 4 Jan 2019
Amneal Names David A. Buchen Senior Vice President, Chief Legal Officer And Corporate Secretary
Amneal Names David A. Buchen Senior Vice President, Chief Legal Officer And Corporate Secretary
HSMN NewsFeed - 30 Nov 2018
AbbVie Announces HUMIRA(R) (adalimumab) Global Patent License with Pfizer
AbbVie Announces HUMIRA(R) (adalimumab) Global Patent License with Pfizer
HSMN NewsFeed - 19 Oct 2018
Mylan and Biocon Announce Positive CHMP Opinion for Ogivri(R), Biosimilar Trastuzumab
Mylan and Biocon Announce Positive CHMP Opinion for Ogivri(R), Biosimilar Trastuzumab
HSMN NewsFeed - 18 Oct 2018
AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Fresenius Kabi
AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Fresenius Kabi
HSMN NewsFeed - 24 Sep 2018
Tocagen Appoints Mohamed Ladha as Vice President to Establish Commercial Organization
Tocagen Appoints Mohamed Ladha as Vice President to Establish Commercial Organization
HSMN NewsFeed - 27 Jul 2018
Accord Healthcare’s (Intas) Pelgraz(R) (pegfilgrastim) Given Green Light by CHMP
Accord Healthcare’s (Intas) Pelgraz(R) (pegfilgrastim) Given Green Light by CHMP
HSMN NewsFeed - 23 Jul 2018
Amneal Announces FDA Approval and Launch of Generic Potassium Chloride Oral Solution
Amneal Announces FDA Approval and Launch of Generic Potassium Chloride Oral Solution
HSMN NewsFeed - 13 Jul 2018
Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY(TM) (romosozumab) To The US FDA
Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY(TM) (romosozumab) To The US FDA
HSMN NewsFeed - 29 Jun 2018
Amneal Announces Favorable Ruling Regarding Patent Validity for Zomig(R) (zolmitriptan) Nasal Spray
Amneal Announces Favorable Ruling Regarding Patent Validity for Zomig(R) (zolmitriptan) Nasal Spray
HSMN NewsFeed - 28 Jun 2018
Lupin and Mylan Partner to Commercialize Enbrel(R) (Etanercept) Biosimilar
Lupin and Mylan Partner to Commercialize Enbrel(R) (Etanercept) Biosimilar
HSMN NewsFeed - 20 Jun 2018
Amneal Announces Patent Litigation Settlement Agreement with Actavis Concerning Rytary(R)
Amneal Announces Patent Litigation Settlement Agreement with Actavis Concerning Rytary(R)
HSMN NewsFeed - 8 Jun 2018
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
HSMN NewsFeed - 4 Jun 2018
Codiak BioSciences Names Richard Brudnick Chief Business Officer and Head of Strategy
Codiak BioSciences Names Richard Brudnick Chief Business Officer and Head of Strategy
HSMN NewsFeed - 30 May 2018
FDA expedites review of Novartis drug Promacta(R) for first-line severe aplastic anemia (SAA)
FDA expedites review of Novartis drug Promacta(R) for first-line severe aplastic anemia (SAA)
HSMN NewsFeed - 23 May 2018
mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States
mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States
HSMN NewsFeed - 18 May 2018
FDA Approves Aimovig(TM) (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention
FDA Approves Aimovig(TM) (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention
HSMN NewsFeed - 15 May 2018
Amneal Introduces First Generic for Mephyton(R) (Phytonadione) Tablets, 5mg
Amneal Introduces First Generic for Mephyton(R) (Phytonadione) Tablets, 5mg
HSMN NewsFeed - 5 Apr 2018
AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Samsung Bioepis
AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Samsung Bioepis
HSMN NewsFeed - 27 Feb 2018
Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta(R) (pegfilgrastim)
Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta(R) (pegfilgrastim)
HSMN NewsFeed - 18 Dec 2017
Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
HSMN NewsFeed - 1 Dec 2017
FDA approves first biosimilar for the treatment of certain breast and stomach cancers
FDA approves first biosimilar for the treatment of certain breast and stomach cancers
HSMN NewsFeed - 28 Sep 2017
AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Amgen
AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Amgen
HSMN NewsFeed - 28 Sep 2017
Amgen And AbbVie Agree To Settlement Allowing Commercialization Of AMGEVITA(TM)
Amgen And AbbVie Agree To Settlement Allowing Commercialization Of AMGEVITA(TM)
HSMN NewsFeed - 17 Jul 2017
Amgen And UCB Provide Update On Regulatory Status Of EVENITY(TM) (romosozumab) In The US
Amgen And UCB Provide Update On Regulatory Status Of EVENITY(TM) (romosozumab) In The US
HSMN NewsFeed - 19 May 2017
Sanofi Receives CHMP Recommendation for Approval of Insulin Lispro Biosimilar
Sanofi Receives CHMP Recommendation for Approval of Insulin Lispro Biosimilar
HSMN NewsFeed - 21 Mar 2017
Forty Seven Inc. Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st
Forty Seven Inc. Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st
HSMN NewsFeed - 13 Mar 2017
Mylan Announces Global Settlement and License Agreements with Genentech and Roche on Herceptin(R)
Mylan Announces Global Settlement and License Agreements with Genentech and Roche on Herceptin(R)
HSMN NewsFeed - 22 Feb 2017
Repatha(R) (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
Repatha(R) (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
HSMN NewsFeed - 9 Jan 2017
Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies
Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies
HSMN NewsFeed - 11 Nov 2016
OncBioMune Broadens Portfolio, Partners and Product with Vitel Acquisition
OncBioMune Broadens Portfolio, Partners and Product with Vitel Acquisition
HSMN NewsFeed - 29 Sep 2016
Amgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations
Amgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations
HSMN NewsFeed - 26 Sep 2016
Pfizer Decides Remaining One Company Best Positions Company To Maximize Future Value Creation
Pfizer Decides Remaining One Company Best Positions Company To Maximize Future Value Creation
HSMN NewsFeed - 1 Aug 2016
Sorrento Therapeutics Announces the Appointment of Dr. Yue Alexander Wu to its Board of Directors
Sorrento Therapeutics Announces the Appointment of Dr. Yue Alexander Wu to its Board of Directors
HSMN NewsFeed - 14 Jul 2016
Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan
Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan
HSMN NewsFeed - 30 May 2016
FLIXABI(R), Biogen’s Infliximab Biosimilar Referencing Remicade(R), Approved in the European Union
FLIXABI(R), Biogen’s Infliximab Biosimilar Referencing Remicade(R), Approved in the European Union
HSMN NewsFeed - 17 Jan 2016
BENEPALI(R), the First Etanercept Biosimilar Referencing Enbrel(R), Approved in the European Union
BENEPALI(R), the First Etanercept Biosimilar Referencing Enbrel(R), Approved in the European Union
HSMN NewsFeed - 4 Dec 2015
Samsung Bioepis' RENFLEXIS(R) Infliximab Biosimilar Receives Regulatory Approval in Korea
Samsung Bioepis' RENFLEXIS(R) Infliximab Biosimilar Receives Regulatory Approval in Korea
HSMN NewsFeed - 4 Nov 2015
Flagship Ventures Launches Evelo Therapeutics To Develop Microbiome Therapies for Cancer
Flagship Ventures Launches Evelo Therapeutics To Develop Microbiome Therapies for Cancer
HSMN NewsFeed - 18 Sep 2015
Momenta Pharmaceuticals Appoints Georges Gemayel, Ph.D., to Board of Directors
Momenta Pharmaceuticals Appoints Georges Gemayel, Ph.D., to Board of Directors
HSMN NewsFeed - 10 Sep 2015
Protagonist Therapeutics Names Richard S. Shames, M.D. as Chief Medical Officer
Protagonist Therapeutics Names Richard S. Shames, M.D. as Chief Medical Officer
HSMN NewsFeed - 27 Aug 2015
Hospira Announces First Installation of Plum 360(TM) Infusion System With Hospira MedNet
Hospira Announces First Installation of Plum 360(TM) Infusion System With Hospira MedNet
HSMN NewsFeed - 6 May 2015
EMD Serono Initiates Co-Promotion of XALKORI(R) (crizotinib) with Pfizer in the United States
EMD Serono Initiates Co-Promotion of XALKORI(R) (crizotinib) with Pfizer in the United States
HSMN NewsFeed - 9 Jul 2014
Coherus BioSciences Appoints Dr. V. Bryan Lawlis, Jr. to Board of Directors
Coherus BioSciences Appoints Dr. V. Bryan Lawlis, Jr. to Board of Directors
HSMN NewsFeed - 12 May 2014
Coherus Biosciences Appoints Lisa M. Bell, Ph.D., Senior Vice President, Global Regulatory Affairs
Coherus Biosciences Appoints Lisa M. Bell, Ph.D., Senior Vice President, Global Regulatory Affairs
HSMN NewsFeed - 28 Apr 2014
Coherus Biosciences Appoints Michael A. Fleming as Senior Vice President, Commercial Strategy
Coherus Biosciences Appoints Michael A. Fleming as Senior Vice President, Commercial Strategy
HSMN NewsFeed - 18 Feb 2014
Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction
Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction
HSMN NewsFeed - 14 Jan 2014
Actavis Appoints Industry Veterans to Lead U.S. Specialty Brands Business Units
Actavis Appoints Industry Veterans to Lead U.S. Specialty Brands Business Units
HSMN NewsFeed - 12 Dec 2013
Momenta Pharmaceuticals Appoints Michael Franken, M.D. as President, Biosimilars Business
Momenta Pharmaceuticals Appoints Michael Franken, M.D. as President, Biosimilars Business
HSMN NewsFeed - 21 Nov 2013
Forest Laboratories and Gedeon Richter Receive Complete Response Letter for Cariprazine
Forest Laboratories and Gedeon Richter Receive Complete Response Letter for Cariprazine
HSMN NewsFeed - 29 Jul 2013
Pfizer To Create Separate, Internal, Global Innovative And Value Businesses
Pfizer To Create Separate, Internal, Global Innovative And Value Businesses
HSMN NewsFeed - 19 Jun 2013
Actavis And Kissei File Lawsuits Against Sandoz And Hetero For Infringement Of Rapaflo(R) Patent
Actavis And Kissei File Lawsuits Against Sandoz And Hetero For Infringement Of Rapaflo(R) Patent
HSMN NewsFeed - 1 May 2013
Actavis Acquires Worldwide Rights for Valeant's Metronidazole 1.3% Vaginal Gel
Actavis Acquires Worldwide Rights for Valeant's Metronidazole 1.3% Vaginal Gel
HSMN NewsFeed - 30 Aug 2012
Teva Announces FDA Grants Approval for Tbo-filgrastim for the Treatment of Chemotherapy-Induced Neutropenia
Teva Announces FDA Grants Approval for Tbo-filgrastim for the Treatment of Chemotherapy-Induced Neutropenia
HSMN NewsFeed - 2 Aug 2012
Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
HSMN NewsFeed - 21 Jun 2012
Nile Therapeutics Appoints Darlene Horton, M.D., as Chief Medical Officer
Nile Therapeutics Appoints Darlene Horton, M.D., as Chief Medical Officer
HSMN NewsFeed - 27 Apr 2012
Watson Announces Restructuring of Senior Leadership to Support Expanded Global Businesses
Watson Announces Restructuring of Senior Leadership to Support Expanded Global Businesses
HSMN NewsFeed - 25 Feb 2011
FDA Issues Complete Response Letter for Taliglucerase Alfa New Drug Application
FDA Issues Complete Response Letter for Taliglucerase Alfa New Drug Application
HSMN NewsFeed - 9 Dec 2010
Teva Announces Successful Results of Phase III Study with Oral Laquinimod for Multiple Sclerosis
Teva Announces Successful Results of Phase III Study with Oral Laquinimod for Multiple Sclerosis
HSMN NewsFeed - 7 Dec 2010
La Jolla Pharmaceutical Company Announces Appointment of Dr. Bertrand C. Liang to Board of Directors
La Jolla Pharmaceutical Company Announces Appointment of Dr. Bertrand C. Liang to Board of Directors
HSMN NewsFeed - 19 Jul 2010
Phage Pharmaceuticals Appoints David Jackson as Vice President, Operations Planning
Phage Pharmaceuticals Appoints David Jackson as Vice President, Operations Planning
HSMN NewsFeed - 8 Oct 2009
Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs
Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs
HSMN NewsFeed - 5 Feb 2009
Dr. Reddy's Announces Five ANDA Approvals and Generic Product Launches in the US Market
Dr. Reddy's Announces Five ANDA Approvals and Generic Product Launches in the US Market
HSMN NewsFeed - 2 Jun 2008
Huge Potential in Biosimilars if Generic Providers Overcome Regulatory Hurdles
Huge Potential in Biosimilars if Generic Providers Overcome Regulatory Hurdles
HSMN NewsFeed - 9 Apr 2008
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in Korea
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in Korea
HSMN NewsFeed - 5 Feb 2008
Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
HSMN NewsFeed - 19 Oct 2007
Hospira's Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
Hospira's Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
HSMN NewsFeed - 14 May 2007
Former Immunex Management Team Chosen to Head-Up CTI Subsidiary Aequus BioPharma, Inc.
Former Immunex Management Team Chosen to Head-Up CTI Subsidiary Aequus BioPharma, Inc.
HSMN NewsFeed - 25 May 2006
Abraxis BioScience Bolsters Manufacturing and Global Operational Expertise With Key Senior Executives
Abraxis BioScience Bolsters Manufacturing and Global Operational Expertise With Key Senior Executives
Additional items found! 1

Members Archive contains
1 additional stories matching:
biosimilar
(Password required)
biosimilar
(Password required)